Retatrutide, a new dual agonist of the GLP-1 binding site and glucose-dependent released polypeptide (GIP) target, is demonstrating promising outcomes in early human trials . Recent inquiry suggests https://bookmarkinglife.com/story7029282/retatrutide-emerging-investigations-and-potential-therapeutic-roles